WalterHealthcareRequest a quote

Oral liquids · Contract manufacturing in India

Cyanocobalamin 2.5 mcg, D-Panthenol 2.5 mg, Niacinamide 30 mg, Pyridoxine 0.75 mg Syrup

Request manufacturing feasibility

Discuss third-party manufacturing of Cyanocobalamin 2.5 mcg, D-Panthenol 2.5 mg, Niacinamide 30 mg, Pyridoxine 0.75 mg Syrup with Walter Healthcare, India. Share your target market, required bottle count and fill volume, packaging and launch timeline for a product-specific quotation.

Catalogue reference
WH-1560
Composition and strength
Cyanocobalamin 2.5 mcg, D-Panthenol 2.5 mg, Niacinamide 30 mg, Pyridoxine 0.75 mg
Dosage form
Syrup
Indicative administration route
Oral
Therapeutic navigation area
Nutrition & supportive care
Pharmacological class
Haematinic & nutritional supplement
Manufacturing stream
Non-beta-lactam

Catalogue details support an initial B2B discussion. Walter confirms the applicable unit, current licence scope, formula, target market and commercial feasibility before making a commitment.

Clinical reference

Mechanism and pharmacokinetics.

Explore the published evidence for the ingredients in Cyanocobalamin 2.5 mcg, D-Panthenol 2.5 mg, Niacinamide 30 mg, Pyridoxine 0.75 mg Syrup. Each reference identifies its source formulation and study context. Ingredient studies describe the named reference product; they do not establish the pharmacokinetics, clinical suitability or bioequivalence of this finished formulation.

How to read our product information and sources ↗

Additional ingredient references still to be verified: D-Panthenol. The references below cover only the named ingredients.

Nutrient reference

Vitamin B12

Reference for: Cyanocobalamin. Source presentation: oral nutrient reference. Source route: oral.

Biological role

Vitamin B12 supplies cofactors for methionine synthase and methylmalonyl-CoA mutase. These reactions support methionine formation and conversion of methylmalonyl-CoA to succinyl-CoA. B12 is involved in DNA synthesis, red-cell formation and nervous-system function.

Absorption and disposition

Free B12 combines with intrinsic factor and is taken up in the distal ileum. Absorption becomes less efficient as the dose exceeds intrinsic-factor capacity; the NIH review reports about 2% absorption at 500 micrograms and 1.3% at 1,000 micrograms. Cyanocobalamin and hydroxocobalamin are converted into active cobalamin forms. These are oral nutrient data, not injectable-product pharmacokinetics.

Nutrient-level summary from NIH. Absorption and disposition describe general oral nutritional physiology, not a pharmacokinetic or bioequivalence study of this finished product.

Source: NIH Office of Dietary Supplements: Vitamin B12

Reference accessed .

Nutrient reference

Vitamin B6

Reference for: Pyridoxine. Source presentation: oral nutrient reference. Source route: oral.

Biological role

Pyridoxal phosphate and pyridoxamine phosphate are active vitamin B6 coenzymes involved in amino-acid metabolism. B6 also contributes to neurotransmitter synthesis, glycogen metabolism and hemoglobin formation.

Absorption and disposition

Vitamin B6 is absorbed in the jejunum. Phosphorylated forms are dephosphorylated before free B6 enters by passive diffusion. The NIH review describes similar absorption from foods and supplements; much of a large pharmacological dose is rapidly eliminated in urine. This physiology does not supply a measured half-life for this formulation.

Nutrient-level summary from NIH. Absorption and disposition describe general oral nutritional physiology, not a pharmacokinetic or bioequivalence study of this finished product.

Source: NIH Office of Dietary Supplements: Vitamin B6

Reference accessed .

Nutrient reference

Niacin and nicotinamide

Reference for: Niacinamide. Source presentation: oral nutrient reference. Source route: oral.

Biological role

Niacin supplies precursors for NAD and NADP. These coenzymes participate in cellular oxidation-reduction reactions, energy metabolism and biosynthetic processes. This nutrient role should not be confused with evidence for a lipid-lowering effect of every niacin form.

Absorption and disposition

Ingested niacin is absorbed mainly in the small intestine, with some stomach absorption. Tissues convert physiological amounts to NAD. Excess is metabolized in the liver to methylated and oxidized products that are eliminated in urine; very high intake can also produce urinary excretion of unchanged nicotinic acid or nicotinamide.

Nutrient-level summary from NIH. Absorption and disposition describe general oral nutritional physiology, not a pharmacokinetic or bioequivalence study of this finished product.

Source: NIH Office of Dietary Supplements: Niacin and nicotinamide

Reference accessed .

Editorial development perspective

What deserves attention in this formulation.

These notes use the catalogue composition and presentation to frame a technical discussion. They are planning considerations, not tested properties or clinical findings for this product.

The clinical references on this page cover only their named ingredients. These development notes do not resolve the remaining clinical-reference gaps.

About these development notes and source limitations ↗

Set a measurable liquid-product target

Listed presentation: Syrup.

Resolve whether the complete formula is intended to remain in solution or contain dispersed material. Compare appearance, pH, viscosity and assay behaviour during development. If flavour or sweetener preferences are part of the brief, evaluate them within that formula rather than accepting a taste-only prototype as the finished technical specification.

Resolve the amount-per-container or concentration basis

Strength expressions in this entry include “2.5 mcg”, “2.5 mg”, “30 mg”, “0.75 mg”.

Clarify whether each stated amount applies to a complete container, a defined volume or a defined weight. Put the agreed denominator beside the ingredient quantity before comparing formula costs or designing a label. Keep the finished fill size as a separate field so that changing the pack does not silently change the intended specification.

Suggested starting point

A practical starting point is to resolve the amount-per-container or concentration basis. For this syrup brief, agree the target characteristics and a short set of measurable development questions before comparing prototypes or supplier proposals. Keep unresolved clinical claims outside the product specification until supporting evidence is available.

Discuss this product brief

Manufacturing & packaging brief

Plan the syrup presentation.

Use this preparation guide for Cyanocobalamin 2.5 mcg, D-Panthenol 2.5 mg, Niacinamide 30 mg, Pyridoxine 0.75 mg Syrup. These are the decisions to resolve with the technical team before a site, process and commercial scope are confirmed.

Presentation & formulation

Specify the ingredient amounts per stated volume and the separate bottle fill volume. Identify flavour, colour and ingredient exclusions as requirements for review.

Quality & technical transfer

Agree the formula, analytical methods and applicable physical and microbiological specifications. Confirm the basis for any proposed storage or label statement.

Review the technical documents

Packaging configuration

Describe the bottle, closure and measuring cup, spoon or syringe. Ask for the container and measuring accessory to be assessed with the formulation.

Explore packaging options

Details to confirm for this record

Full composition
Keep all named components and their individual amounts together in the specification. Ingredient substitutions, omissions and changed ratios require a separate formula and permission review.
Concentration and pack size
The record does not state a complete concentration basis. Confirm the amount per volume or weight before a specification, label or quotation is finalised; no denominator has been assumed here.

Quantities, MOQ & lead time

For Cyanocobalamin 2.5 mcg, D-Panthenol 2.5 mg, Niacinamide 30 mg, Pyridoxine 0.75 mg Syrup (WH-1560), state the bottle count and fill volume, target market and reorder forecast. MOQ and lead time depend on the assessed formula, process, components, testing and project readiness; request those terms in writing.

Discuss this manufacturing brief

Explore the context

Build the right manufacturing brief.

Dosage-form capabilitiesOral liquidsTherapeutic navigationNutrition & supportive careFull catalogueSearch other compositions

Related catalogue records

Grouped by catalogue navigation labels, not by therapeutic interchangeability or clinical recommendation.

Common questions

Before you request a quotation.

Cyanocobalamin 2.5 mcg, D-Panthenol 2.5 mg, Niacinamide 30 mg, Pyridoxine 0.75 mg Syrup

What is listed in the catalogue?

The catalogue lists Cyanocobalamin 2.5 mcg, D-Panthenol 2.5 mg, Niacinamide 30 mg, Pyridoxine 0.75 mg as syrup in its nutrition & supportive care navigation area and non-beta-lactam manufacturing stream.

How do you confirm manufacturing availability?

Send Walter your requirement for Cyanocobalamin 2.5 mcg, D-Panthenol 2.5 mg, Niacinamide 30 mg, Pyridoxine 0.75 mg Syrup. The team reviews the applicable product permission and unit, formulation and equipment fit, testing, packaging and production schedule before confirming the manufacturing scope in writing. Request the relevant product and facility documents with your enquiry.

What do I need for a quotation?

Share the exact composition and strength, syrup presentation, target market, initial quantity, preferred pack and timing. Identify whether this is a new product, development brief or transfer.

The quotation must confirm MOQ, inclusions, prerequisites and lead time for the proposed product and site.

What is needed for Indian and export markets?

For India, share the intended brand or institutional supply requirement, pack sizes, initial order quantity and artwork needs for Cyanocobalamin 2.5 mcg, D-Panthenol 2.5 mg, Niacinamide 30 mg, Pyridoxine 0.75 mg Syrup. Confirm the applicable product permission, manufacturing unit and labelling requirements with the team.

For export, identify each destination country, proposed pack, language and registration or dossier requirements. Ask which product-specific quality and stability documents are available. Container compatibility and destination-market requirements need review; a catalogue record does not establish export registration or a shelf-life commitment.

How do I submit my enquiry?

Use the product-specific enquiry button to carry this composition and dosage form into the form. After a successful submission, a receipt reference confirms that your brief has been saved for review. Use the RFQ checklist to prepare the remaining details.

Technical document review

Which documents can I ask Walter to review?

Ask about manufacturing and packing records, specifications, analytical methods, Certificates of Analysis (COA), stability evidence, the Process Validation Protocol (PVP) and Process Validation Report (PVR). The wider checklist below covers supplier qualification, technical transfer and ongoing supply.

View the full document checklist 14 review areas
Site, licence and audit scope
Manufacturing licence, applicable product permissions, GMP certificates, Site Master File, supplier-qualification questionnaire and relevant audit responses.
Manufacturing, packing and batch release
Master Formula Record (MFR), master packing instructions, Batch Manufacturing Record (BMR), Batch Packing Record (BPR), reconciliation and authorised release records.
Process validation and continued verification
Process Validation Protocol (PVP), Process Validation Report (PVR), process performance qualification documents and continued process verification trends.
Equipment, facilities and utilities
Validation Master Plan (VMP), user requirements, DQ/IQ/OQ/PQ records, calibration and maintenance evidence for relevant equipment and utilities.
Cleaning, carryover and hold times
Cleaning Validation Protocol (CVP), Cleaning Validation Report (CVR), residue limits, recovery studies and applicable clean, dirty and process hold-time studies.
Specifications and analytical evidence
Specifications, Method of Analysis (MOA), Standard Testing Procedure (STP), Certificates of Analysis (COA), analytical validation, verification and method-transfer records.
Stability, packaging and transport
Stability protocols/reports, ongoing stability commitments, pack specifications, approved artwork, compatibility and applicable packaging or transport studies.
Development and technology transfer
Development report, technology-transfer protocol/report, gap assessment, control strategy, critical quality attributes and critical process parameters.
Quality reviews, investigations and changes
Product Quality Review (PQR) / Annual Product Review (APR), deviations, CAPA, change control, OOS/OOT trends, complaints, recalls and relevant SOP/training records.
Material suppliers and impurity risks
API/excipient supplier qualification, traceability, material COAs, relevant origin declarations and impurity risk assessments with supporting tests.
Sterile-product evidence, where applicable
Contamination Control Strategy (CCS), media-fill/aseptic simulation reports, sterilisation and filtration validation, environmental monitoring, sterility/endotoxin and container-closure integrity evidence.
Computerised systems and data integrity
Computerised-system validation, access controls, audit-trail review, backup/restore checks and relevant data-integrity procedures.
Market-specific regulatory support
Applicable dossier sections, API master-file/CEP support, bioequivalence or biowaiver evidence and Certificate of a Pharmaceutical Product (CPP/CoPP), where required and available.
Quality agreement and access arrangements
Quality/technical agreement covering responsibilities, release, changes, subcontracting, investigations, complaints, recalls, audits and document access.

Agree the list for the exact product, site, process, pack, market and project stage. QA confirms what exists, applies and may be shared; some records may require an NDA, redaction or controlled review. See document definitions and review guidance.

Important qualification

This B2B catalogue record is not proof of current approval or confirmation that Cyanocobalamin 2.5 mcg, D-Panthenol 2.5 mg, Niacinamide 30 mg, Pyridoxine 0.75 mg Syrup is available for sale. It is not prescribing information or patient advice. Any Drugs Rules status, current approval, exemption, applicable unit, licence scope, formulation, claims, brand use, destination-market registration and commercial feasibility require documentary verification and Walter's written confirmation. Read the full regulatory disclaimer.

Composition and classification are taken from Walter's product catalogue. The manufacturing guide helps buyers prepare a technical brief. Clinical references, where shown, describe the cited product and study. Manufacturing guide updated .